Literature DB >> 33447132

Expression of Circulating MicroRNA-141 in Epithelial Ovarian Cancer.

Akbar Satria Fitriawan1, Aprilia Indra Kartika2, Siti Nur Chasanah3, Teguh Aryandono4, Sofia Mubarika Haryana5.   

Abstract

BACKGROUND: Epithelial ovarian cancer (EOC) is a lethal disease due to late diagnosis and lack of effective screening methods. MicroRNA (miR/miRNA) plays an important role in ovarian carcinogenesis and may serve as a non-invasive biomarker for EOC. This study aimed to assess miR-141 expression in the blood plasma of patients with EOC and healthy subjects and determine its association with the clinical stage of EOC.
METHODS: This cross-sectional study used blood plasma from 30 newly diagnosed untreated patients with EOC and 25 healthy subjects. The mean age was 47.73 (SD = 10.29) years for EOC and 44.48 (SD = 16.14) years for healthy subject. The total RNA was isolated from blood plasma and reversed transcribed to obtain cDNA. The expression of miR-141 was measured by real-time quantitative polymerase chain reaction (qRT-PCR), and calculated using 2-ΔΔCt methods. The data were analysed using Mann-Whitney test.
RESULTS: The expression of miR-141 was upregulated 8.41 fold in the blood plasma of EOC patients compared to healthy controls (P < 0.001). Expression of miR-141 in the advanced stage was upregulated 4.2 fold compared to the early stage (P < 0.001).
CONCLUSION: The miR-141 was upregulated in the blood plasma of EOC and associated with an advanced stage of disease, suggesting it has potential as a biomarker for EOC detection. © Penerbit Universiti Sains Malaysia, 2020.

Entities:  

Keywords:  biomarker; epithelial ovarian cancer; miR-141; microRNA; plasma

Year:  2020        PMID: 33447132      PMCID: PMC7785261          DOI: 10.21315/mjms2020.27.6.4

Source DB:  PubMed          Journal:  Malays J Med Sci        ISSN: 1394-195X


  74 in total

1.  Combinatorial microRNA target predictions.

Authors:  Azra Krek; Dominic Grün; Matthew N Poy; Rachel Wolf; Lauren Rosenberg; Eric J Epstein; Philip MacMenamin; Isabelle da Piedade; Kristin C Gunsalus; Markus Stoffel; Nikolaus Rajewsky
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

2.  Circulating miRNAs are correlated with tumor progression in prostate cancer.

Authors:  Jan C Brase; Marc Johannes; Thorsten Schlomm; Maria Fälth; Alexander Haese; Thomas Steuber; Tim Beissbarth; Ruprecht Kuner; Holger Sültmann
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

3.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

Review 4.  Epithelial ovarian cancer.

Authors:  Stephanie Lheureux; Charlie Gourley; Ignace Vergote; Amit M Oza
Journal:  Lancet       Date:  2019-03-23       Impact factor: 79.321

Review 5.  PTEN, a unique tumor suppressor gene.

Authors:  P L Dahia
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

6.  Epithelial ovarian cancer: An overview.

Authors:  Arpita Desai; Jingyao Xu; Kartik Aysola; Yunlong Qin; Chika Okoli; Ravipati Hariprasad; Ugorji Chinemerem; Candace Gates; Avinash Reddy; Omar Danner; Geary Franklin; Anachebe Ngozi; Guilherme Cantuaria; Karan Singh; William Grizzle; Charles Landen; Edward E Partridge; Valerie Montgomery Rice; E Shyam P Reddy; Veena N Rao
Journal:  World J Transl Med       Date:  2014-04-12

7.  MiR-141-3p is upregulated in esophageal squamous cell carcinoma and targets pleckstrin homology domain leucine-rich repeat protein phosphatase-2, a negative regulator of the PI3K/AKT pathway.

Authors:  Osamu Ishibashi; Ichiro Akagi; Yota Ogawa; Takashi Inui
Journal:  Biochem Biophys Res Commun       Date:  2018-05-16       Impact factor: 3.575

8.  PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms.

Authors:  John Brognard; Emma Sierecki; Tianyan Gao; Alexandra C Newton
Journal:  Mol Cell       Date:  2007-03-23       Impact factor: 17.970

9.  miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.

Authors:  M T M van Jaarsveld; J Helleman; A W M Boersma; P F van Kuijk; W F van Ijcken; E Despierre; I Vergote; R H J Mathijssen; E M J J Berns; J Verweij; J Pothof; E A C Wiemer
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

10.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Authors:  Saundra S Buys; Edward Partridge; Amanda Black; Christine C Johnson; Lois Lamerato; Claudine Isaacs; Douglas J Reding; Robert T Greenlee; Lance A Yokochi; Bruce Kessel; E David Crawford; Timothy R Church; Gerald L Andriole; Joel L Weissfeld; Mona N Fouad; David Chia; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Patricia Hartge; Paul F Pinsky; Claire S Zhu; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; Jian-Lun Xu; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  JAMA       Date:  2011-06-08       Impact factor: 157.335

View more
  3 in total

1.  Identification of Stably Expressed Reference microRNAs in Epithelial Ovarian Cancer.

Authors:  Joanna Lopacinska-Joergensen; Douglas V N P Oliveira; Claus K Hoegdall; Estrid V Hoegdall
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

Review 2.  The role of miR-200 family in the regulation of hallmarks of cancer.

Authors:  Klaudia Klicka; Tomasz M Grzywa; Aleksandra Mielniczuk; Alicja Klinke; Paweł K Włodarski
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

3.  Prognostic and clinicopathological value of circPVT1 in human cancers: A meta-analysis.

Authors:  Zhengjun Lin; Xianzhe Tang; Lu Wang; Lin Ling
Journal:  Cancer Rep (Hoboken)       Date:  2021-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.